Market Place
Sourcing Support
Sigma`s Biologic Oncaspar (Pegaspargase) Receives Approval in the U.S.
22 Dec 2022 //
FDA
Analysis Suggest Pediatric-Inspired Regimens Lead to Higher Survival in Patient
12 Dec 2022 //
PRNEWSWIRE
Jazz Presents Positive Interim Phase 2/3 Results of Rylaze in ALL and LBL
11 Dec 2021 //
PRNEWSWIRE
Servier`s Asparlas (calaspargase pegol) Receives Supplemental Approval In US
26 Jun 2020 //
FDA
Sigma Tau`s Oncospar (Pegaspargase) Receives Supplemental Approval in US
24 Jun 2020 //
FDA
ERYTECH Announces Publication of its Phase 2b Trial of Eryaspase
25 Nov 2019 //
BIO SPACE
US sanctions on Iran threaten access to certain medicines: report
30 Oct 2019 //
REUTERS
Half of European cancer drug trials ‘biased’, says BMJ
21 Sep 2019 //
PMLIVE
Letters and drug alerts sent to healthcare professionals in July 2019
19 Aug 2019 //
GOVUK
Servier, armed with Shire cancer drugs, builds out vision for U.S. future
08 Jun 2019 //
FIERCE PHARMA
Servier`s Calaspargase Pegol-Mknl Receive Supplemental Approval in US
20 Dec 2018 //
FDA
Novartis, Pfizer, AZ and more hand China 50%-plus cancer drug discounts
11 Oct 2018 //
FIERCE PHARMA
Shire completes sale of oncology franchise to Servier
31 Aug 2018 //
PHARMA TIMES
Immunology keeps Shire figures solid as Takeda takeover nears
31 Jul 2018 //
PM LIVE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.